OptiBiotix Health PLC

OptiBiotix Health aiming to be big in Japan with latest deal

Following hard on the heels of a commercial deal covering the Baltic area, OptiBiotix Health plc (LON:OPTI) has signed an agreement that will see its breakthrough cholesterol-lowering bacteria strain distributed in Japan. Founder and CEO Stephen O'Hara talks Proactive London through OptiBiotix's last two RNS's and explains how they are inter-related. O'Hara also explains how he has an eye for an emerging trend and how this product, in his view, is one of those key moments.
For the UK group has negotiated an exclusive tie-up with the EIWA Trading Co for its LPLDL product. OptiBiotix will ship an agreed minimum volume of the cholesterol and blood pressure-reducing probiotic, Lactobacillus plantarum, which rises over the term of the three-year contract.

Quick facts: OptiBiotix Health PLC

Price: £0.48

Market: AIM
Market Cap: £41.01 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...



Full interview: European healthcare broker sets 97p price target for...

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara speaks to Proactive London following a research note whcih has been published on the company by Goetz partners - which has set OPTI a price target of 97p. O'Hara says Goetz partners are a leading European Investment Bank and broking firm and...

1 week, 4 days ago

2 min read